Vol. 6 No. 6 (2026): June
Reimbursement Recommendations

Bimekizumab (Bimzelx)

decorative image of the issue cover

Published June 2, 2026

Key Messages

What Is the Reimbursement Recommendation for Bimzelx?

  • The Canada’s Drug Agency (CDA-AMC) Canadian Drug Expert Committee (CDEC) recommends that Bimzelx be reimbursed by public drug plans for the treatment of adult patients with moderate to severe hidradenitis suppurativa (HS) with an inadequate response to conventional systemic therapy for HS only if certain conditions are met. [What Is the Reimbursement Recommendation For XXX?]

Which Patients Are Eligible for Coverage?

  • Bimzelx should only be covered to treat patients who have moderate to severe HS (Hurley stage II or III), a total abscess and nodule count of 5 or greater, lesions in at least 2 separate areas of the body, and whose HS did not adequately respond to conventional therapy. [Which Patients Are Eligible for Coverage?]

What Are the Conditions for Reimbursement?

  • Bimzelx should only be reimbursed if prescribed by a physician experienced in the management of HS and should not be reimbursed if used in combination with other biologic therapies for HS. Bimzelx should be reimbursed for ongoing treatment if there is improvement in HS after starting treatment with Bimzelx. The price of Bimzelx should be negotiated so that its total drug cost does not exceed the total drug cost of treatment with the lowest-cost adalimumab.